Category: Pharmaceuticals
-
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
•
Successfully navigating the stock market requires patience and a long-term perspective. The key is to stick to a consistent plan and make regular contributions to a retirement account, allowing the power of compounding to work its magic over time. However, there is an undeniable appeal in searching for potential multibagger…
-
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
•
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Breadcrumb Trail Links GlobeNewswire Author of the article: Published Dec 20, 2024 • 8 minute…
-
Terns Pharmaceuticals director buys $5 million in company stock By Investing.com
•
In a recent deal, Hongbo Lu, a director at Terns Pharmaceuticals, Inc. (NASDAQ:TERN), bought a significant amount of the company’s stock, signaling a strong vote of confidence in the company’s future prospects. The deal, which closed on September 12, involved the acquisition of 476,190 shares at $10.50 per share, for…
-
Terns Pharmaceuticals director buys $5 million in company stock By Investing.com
•
In a recent deal, Hongbo Lu, a director at Terns Pharmaceuticals, Inc. (NASDAQ:TERN), bought a significant amount of the company’s stock, signaling a strong vote of confidence in the company’s future prospects. The deal, which closed on September 12, involved the acquisition of 476,190 shares at $10.50 per share, for…
-
Lexicon Pharmaceuticals reported a net loss of $53.4 million By Investing.com
•
Lexicon Pharmaceuticals (NASDAQ: NASDAQ:) reported in their second quarter 2024 earnings call a modest growth in their INPEFA business and a net loss of $53.4 million. The company highlighted the resubmission of their New Drug Application (NDA) for Zynquista, the advancement of their Phase 3 study for Sotagliflozin in hypertrophic…
-
Medexus Pharmaceuticals posts record annual revenue By Investing.com
•
Medexus Pharmaceuticals (MDP.V) has announced a record revenue of $113.1 million for the fiscal year 2024, along with a positive adjusted EBITDA of $19.5 million. Despite a decrease in revenue and gross profit for the fourth quarter, the company remains optimistic about the future, particularly with the potential approval of…
-
Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference By Investing.com
•
Washington, May 30, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (NASDAQ:) Vanda (Nasdaq: VNDA) announced today that the company will participate in the Jefferies 2024 Global Healthcare Conference in… New York City on Thursday, June 6, 2024. A corporate presentation is scheduled 2:00 PM EST. The company’s presentation at the Jefferies…
-
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting By Investing.com
•
– Seven summaries highlighting ALGS and PFIC data, including three oral presentations – Long-term extension data from the phase III PFIC study were presented in plenary and selected from among the highest-scoring abstracts FOSTER CITY, Calif.–( BUSINESS WIRE )–Mirom Pharmaceuticals (Nasdaq: MIRM) today announced data presented at the 56th Annual…